Abstract:In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is 'fully human', T cell epitopes that are contained in the sequences of the biologic may activate the immune system, enabling the development of anti-drug antibodies that can reduce drug efficacy and may contribute to adverse events. Computational tools that identify T cell epitopes from primary amino acid sequences have been used to assess the immunogenic potential of therapeutic candidates for several decades. To facilitate larger scale analyses and accelerate preclinical immunogenicity risk assessment, our group developed an integrated web-based platform called ISPRI, (Immunogenicity Screening and Protein Re-engineering Interface) that provides hands-on access through a secure web-based interface for scientists working in large and mid-sized biotech companies in the US, Europe, and Japan. This toolkit has evolved and now contains an array of algorithms that can be used individually and/or consecutively for immunogenicity assessment and protein engineering. Most analyses start with the advanced epitope mapping tool (EpiMatrix), then proceed to identify epitope clusters using ClustiMer, and then use a tool called JanusMatrix to define whether any of the T cell epitope clusters may generate a regulatory T cell response which may diminish or eliminate anti-drug antibody formation. Candidates can be compared to similar products on a normalized immunogenicity scale. Should modifications to the biologic sequence be an option, a tool for moderating putative immunogenicity by editing T cell epitopes out of the sequence is available (OptiMatrix). Although this perspective discusses the in-silico immunogenicity risk assessment for monoclonal antibodies, bi-specifics, multi-specifics, and antibody-drug conjugates, the analysis of additional therapeutic modalities such as enzyme replacement proteins, blood factor proteins, CAR-T, gene therapy products, and peptide drugs is also made available on the ISPRI platform. ISPRI (Interactive Screening and Protein Reengineering Interface) : Integrated, cloud-based, comprehensive toolkit for Immunogenicity Risk Assessment. EpiMatrix Immunogenicity Score : Combined T effector and Treg Epitope Content per unit protein. Tregitopes : Treg Epitopes found in IgG Framework that have been shown to modulate antigen-specific effector T cell responses. ClustiMer : Tool for identifying epitope rich polypeptides from within a given protein sequence. JanusMatrix : Tool for Predicting Tolerance, Putative Treg Epitopes, and Anti-self-immune responses. OptiMatrix : Tool for modifying T cell epitope sequences to reduce (or enhance) MHC binding.

Prediction of immunogenicity for humanized and full human therapeutic antibodies

AbImmPred: An immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features

Identifying the Epitope Regions of Therapeutic Antibodies Based on Structure Descriptors

Predicting Immunogenicity Risk in Biopharmaceuticals

HAIRpred: Prediction of human antibody interacting residues in an antigen from its primary structure

In Silico Immunogenicity Assessment of Therapeutic Peptides

<i>In Silico</i> Immunogenicity Assessment of Therapeutic Peptides

Accurate prediction of CDR-H3 loop structures of antibodies with deep learning

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies

Prospects for the computational humanization of antibodies and nanobodies

A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffers

Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2

Improving B-cell Epitope Prediction and Its Application to Global Antibody-Antigen Docking.

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning

H3-OPT: Accurate prediction of CDR-H3 loop structures of antibodies with deep learning

AB-Amy: machine learning aided Amyloidogenic risk prediction of therapeutic antibody light chains

Interpretable antibody-antigen interaction prediction by introducing route and priors guidance

Antibody optimization enabled by artificial intelligence predictions of binding affinity and naturalness

Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications

Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability